Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 23S ribosomal RNA (23S rRNA) is the catalytic core of the 50S large ribosomal subunit in bacteria, functioning as a ribozyme that facilitates protein synthesis. It contains the peptidyl transferase center (PTC), which is responsible for catalyzing the formation of peptide bonds between amino acids during translation elongation. By providing the structural framework for the A-site and P-site tRNA binding, the 23S rRNA ensures the correct positioning of substrates for the nucleophilic attack necessary for polypeptide growth. This molecule is a critical therapeutic target for numerous classes of antibiotics, including macrolides, oxazolidinones, lincosamides, and pleuromutilins. These drugs typically bind to the PTC or the adjacent nascent peptide exit tunnel (NPET), effectively halting bacterial growth by obstructing the passage of the emerging protein or inhibiting the catalytic activity of the ribosome. Resistance to these antibiotics often arises through specific point mutations in the 23S rRNA sequence or through enzymatic modification, such as methylation by Erm-class methyltransferases. Because human mitochondrial ribosomes share structural similarities with bacterial ribosomes, some drugs targeting the 23S rRNA can lead to off-target toxicity, such as myelosuppression or neuropathy, due to the inhibition of mitochondrial protein synthesis.
Inhibition of bacterial protein synthesis by binding to the peptidyl transferase center or the nascent peptide exit tunnel, thereby preventing peptide bond formation or polypeptide elongation.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 23S ribosomal RNA (23S rRNA) (23S rRNA).